Personalized Anticancer Agent Screening via Xenograft Verification

The patent uses patient-derived cancer cells as a copy of the patient's actual cancer tissue, which can be cultured and tested in vitro to predict in vivo response. This copying approach allows verification of therapeutic effectiveness without requiring actual patient trials, thus improving reliability while reducing time loss.

The patent introduces xenograft animal models as an intermediary system between in vitro cell culture and actual patient treatment. The animal models serve as a intermediate verification step that can predict human therapeutic response more accurately than cell culture alone, while avoiding the need for time-consuming and risky patient trials.

The patent segments the personalized screening process into distinct stages: in vitro screening of patient cancer cells followed by in vivo verification using xenograft animal models. This segmentation allows the most resource-intensive in vivo testing to be performed only on a reduced set of candidate agents that have already shown promise in preliminary in vitro tests, thus maintaining adaptability while reducing overall cost and time.

The patent performs preliminary in vitro screening of multiple candidate anticancer agents against patient-derived cancer cells before proceeding to more expensive and time-consuming in vivo verification. This preliminary action filters out ineffective agents early, reducing the number of candidates that require resource-intensive subsequent testing, thereby lowering overall costs and time requirements.